#China #Shenzhen #MGI Tech #DNBSEQ-T1+ #CE Mark

MGI Tech Celebrates CE Mark Certification for DNBSEQ-T1+

MGI Tech Co., Ltd., renowned for developing innovative tools and technologies in life sciences, has recently announced a significant achievement. On June 20, 2025, the company officially gained CE mark certification for its latest mid-throughput sequencer, the DNBSEQ-T1+. This certification is crucial as it facilitates the entry of T1+ into the European market for both research and clinical applications, marking a pivotal moment in the company’s global expansion strategy.

Overview of DNBSEQ-T1+

Unveiled during the AGBT 2025 conference, the T1+ serves as MGI's flagship benchtop sequencer, designed with mid-throughput capabilities in mind. The sequencer is distinguished by its speed, allowing for sequencing workflows of 150 paired-end reads in just 24 hours, achieving an impressive quality score of Q40. This makes the T1+ one of the fastest mid-throughput sequencers available today.

Equipped with three flow cell formats and offering anywhere from two to four addressable lanes per flow cell, the T1+ stands out for its remarkable versatility. It supports data outputs ranging from 25 to 1,200 GB, enabling researchers to conduct independent experiments on a single platform, thereby significantly enhancing lab efficiency and flexibility.

Enhanced User Experience and Versatility

Beyond its advanced features, the T1+ includes fully integrated systems for DNB generation and loading, along with an embedded bioinformatics module. These additions streamline the user experience by simplifying workflows and enabling a broader array of genomic applications. This operational efficiency not only increases productivity in various research endeavors but also accommodates diverse investigative requirements.

Duncan Yu, the President of MGI, expressed confidence in the T1+'s potential to advance genomic research, stating, "The CE mark firmly establishes that T1+ fully complies with the EU’s standards and regulations for research and clinical applications. We believe that the availability of T1+ will significantly propel advancements in genomics, empowering researchers and medical professionals in the EU to progress in areas like precision medicine and oncology with its efficient, accurate, and versatile sequencing capabilities."

The T1+ made its debut earlier this year at the ESHG European market fair, generating substantial interest among attendees eager to explore its practical applications and hands-on experience.

About MGI Tech

Founded in 2016, MGI Tech Co., Ltd. is dedicated to developing essential tools and technologies that drive innovation in life sciences. The organization focuses on research and development, manufacturing, and selling instruments, reagents, and products related to life sciences and biotechnology. MGI is committed to providing real-time multi-omics technology and a comprehensive range of digital systems and equipment for precision medicine, agriculture, healthcare, and other industries.

Recognized as a leader within the life sciences sector, MGI serves clients across six continents and has established research, manufacturing, training, and after-sales service centers worldwide. One of the few companies capable of independently developing and mass-producing clinical-grade genetic sequencers with various throughput capacities, MGI continues to shape the future of life sciences through its unparalleled expertise and cutting-edge products.

For more information about MGI Tech, please visit mgi-tech.com or follow us on LinkedIn, X, and YouTube.